Idorsia Ltd is reaching out for more - We have more ideas, we see more opportunities and we want to help more patients.
In order to achieve this, we will develop Idorsia into one of Europes leading biopharmaceutical company, with a strong scientific core.
Headquartered in Switzerland - a European biotech hub - Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet the ideal constellation to bringing R&D efforts to business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 600 highly qualified specialists dedicated to realizing our ambitious targets.
Drug Discovery Biology at Idorsia Pharmaceuticals Ltd is seeking a highly motivated postdoctoral research fellow to join an interdisciplinary research team in Cell metabolism and Oncology for up to two years. The successful candidate will investigate the mechanism of a tumor-suppressive enzyme and protein trafficking. The molecular mode of action exerted by distinct metabolites displaying altered concentrations in tumor tissues is of major interest. The expectation is that this work will result in a better understanding of the mechanisms of tumor immune escape translating into novel small-molecule therapeutic approaches to restore anti-tumor immune surveillance and potentiate immunotherapy. The ideal candidate is an innovative scientist with experience in human cell biology, immunology, biochemistry and molecular biology.
Design and execute experiments addressing the molecular mode of action of immune-suppressive metabolites and associated enzymes in relevant cellular in vitro models including spatial and temporal resolution
Study mode of interaction of tumor and immune cells to identify downstream pathways resulting in anti-proliferative and immune-suppressive effects
Molecular and biochemical characterization of proteins involved in immune suppressive pathways
Preparation of data summaries and reports to efficiently communicate and integrate outcome of experimental studies
Contribute to cell metabolism/oncology group laboratory resources, maintenance, development and management
Candidates should have a PhD degree in either cell biology, immunology, biomedical science or related disciplines
Mastering of basic and advanced molecular biology techniques (e.g., PAGE, WB, ELISA, molecular cloning, plasmid vectors engineering, transfection, and extraction of RNA, DNA and protein) flow cytometry (experimental/panel design and analysis) and sterile cell culture techniques are required
Proven record of research including peer-reviewed publications, and excellent communication skills
Strong ability to interpret data and to troubleshoot and resolve technical issues
Ability to plan, organize and meet deadlines, and work collaboratively in a multidisciplinary research environment
Exciting opportunities for development and professional growth within our dynamic organization
A collaborative and solution-oriented environment where you can make a difference
An innovative and open culture in a truly multicultural environment
A competitive salary and generous social benefits
Business Area:Drug Discovery Biology
Job Type: Temporary
If you are interested, please click on apply now.
Please be informed that if you are selected for this position, your employment will be subject to a pre-employment background screening process, of which you would be informed in greater detail in due course.
Please note Idorsia operates a strictly-controlled list of preferred recruitment partners. For those partners who have no valid, signed Master Service Agreement in place with Idorsia all unsolicited resumes, CVs, anonymous profiles, or any other candidate details submitted through our website or to personal e-mail accounts of employees of Idorsia Pharmaceuticals (including any of its subsidiaries, affiliates or related companies) are considered the property of Idorsia Pharmaceuticals and are not subject to payment of any form of introduction, placement or referral fees.